8月19日，海思科获德邦证券买入评级，近一个月海思科获得2份研报关注。
研报预计公司2024-2026年收入为39.1、49.9、66.2亿元，同比增长16.5%、27.7%、32.6%；同期归母净利润为4.07、7.61、11.7亿元，同比增长38%、86.9%、53.7%。研报认为，随着创新药新产品的上市，商业化将迎来新的增长动能，公司今年催化众多。
风险提示：临床研发失败风险、销售不及预期风险、政策风险等。
- Headlines
- 海思科获德邦证券买入评级，业绩稳健，有望进入创新兑现爆发期
海思科获德邦证券买入评级，业绩稳健，有望进入创新兑现爆发期
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.